The exchange centers on a study by Sanmoto and colleagues, published in the same journal on 12 September 2026, in which the researchers developed and evaluated a deep learning model for computer-aided diagnosis of neonatal pneumothorax on chest radiographs. Deep learning models of this kind are trained on large sets of labeled X-ray images, learning to recognize the visual signatures of air collecting in the pleural space around a lung. In adults, such tools have advanced rapidly, but the newborn chest presents a far harder problem: small lungs, thymic shadows, respiratory support devices, skin folds and atelectasis all conspire to create images where air collections and normal structures can be genuinely difficult to tell apart, even for experienced readers.

The Turkish authors’ reply, published on 8 October 2026, does not dispute the technical achievement of building such a model. Their concern is conceptual and clinical. A pneumothorax in a newborn is not a binary event with uniform consequences. Some air leaks are small, asymptomatic and resolve on their own under observation. Others are tension pneumothoraces, in which accumulating air shifts the mediastinum, compresses the contralateral lung, impairs venous return and threatens cardiovascular collapse within minutes. A detection system that performs well on the average case but stumbles on the tension physiology that demands immediate needle decompression would score respectably on paper while failing precisely where it matters most.

This is why the correspondence invokes the question in its title: does the model detect the neonatal pneumothoraces that matter most? Overall accuracy, the authors argue, blends together easy and hard cases, clinically trivial and clinically urgent findings, into a single figure that can mask systematic blind spots. In a dataset where small pneumothoraces outnumber large ones, a model could achieve high accuracy while missing a disproportionate share of the large, dangerous leaks. Conversely, sensitivity reported across all pneumothoraces tells clinicians nothing about sensitivity restricted to the subset requiring intervention. The metrics that matter for deployment are stratified ones, broken down by size, laterality, tension features and the patient’s clinical status.

The reply grounds this argument in the evolving evidence on how neonatal pneumothorax should be managed. Tatar and colleagues cite work by Baillie and colleagues, published in 2026 in the journal Children, which explored whether simple radiographic measurements can predict the need for intervention in neonatal pneumothorax. That line of research reflects a broader shift in neonatology toward tailoring treatment to severity rather than treating every radiographically visible air leak identically. If radiologists and neonatologists increasingly use measurements on the film to decide who needs a chest drain and who can be watched, then an AI system intended to support those decisions must be evaluated against the same clinically meaningful thresholds, not against a generic label of pneumothorax present or absent.

Management evidence reinforces the stakes. The authors also point to a randomized clinical trial by Murphy and colleagues, published in JAMA Pediatrics in 2018, which examined the effect of needle aspiration of pneumothorax on subsequent chest drain insertion in newborns. That trial is part of the movement toward less invasive first-line treatment for symptomatic air leaks in neonates, an approach that reduces drain placement in many infants. But selective, less invasive management depends entirely on accurate, timely characterization of the leak. If the imaging assessment that feeds into those decisions is delegated partly to an algorithm, the algorithm’s errors propagate directly into triage: a missed significant pneumothorax delays decompression, while a false alarm on an incidental small leak can trigger an unnecessary invasive procedure in a fragile premature infant.

The technical implications for model development are substantial. Training and validating a neonatal pneumothorax detector on binary labels alone invites the very failure mode the correspondence describes. A more clinically attuned pipeline would annotate lesions by size and tension features, weight the loss function toward the high-severity cases, and report performance separately for clinically significant versus clinically insignificant pneumothoraces. External validation on datasets from different scanners, different patient populations and different levels of prematurity would test whether the model generalizes beyond its development environment. Calibration, too, deserves attention: a model that outputs a probability should have that probability mean what it claims, because downstream triage thresholds are only meaningful if the underlying scores are trustworthy.

None of these caveats diminish the promise of computer-aided diagnosis in the neonatal intensive care unit. Chest radiography remains the first-line imaging modality for suspected air leak in newborns, and interpretation is subject to interobserver variability, fatigue and the time pressures of a busy unit. A well-validated AI system could serve as a second reader, flagging studies that need urgent review and reducing the chance that a tension pneumothorax sits unnoticed while a radiologist works through a queue. The point raised by Tatar, Yılmaz and Köker Özer is that realizing this promise requires evaluation frameworks aligned with clinical reality, not just with classification benchmarks. The reply, notably, was prepared with the assistance of ChatGPT for language refinement and editorial organization, with the authors critically reviewing the output and taking full responsibility for the content, an example of the transparency about AI use that journals increasingly expect.

The exchange also illustrates the healthy function of the Matters Arising format itself. Rather than letting an optimistic headline metric stand unchallenged, the correspondence process allows the community to interrogate what a result actually demonstrates and what it does not. Sanmoto and colleagues’ model represents a genuine step toward computer-aided diagnosis of neonatal pneumothorax, and the reply does not assert that the model fails; it insists that the evidence presented does not yet answer the question of whether the pneumothoraces that matter most are being caught. That distinction between not proven and disproven is exactly the kind of nuance that rigorous scientific debate is designed to surface, and it is a nuance that single-number summaries in press releases and abstracts tend to erase.

For clinicians, developers and regulators watching AI enter pediatric imaging, the lesson of this exchange is portable well beyond one model and one disease. Every deployment of diagnostic AI should begin by asking which errors are acceptable and which are catastrophic, and then demand performance data stratified accordingly. In neonatal pneumothorax, the catastrophic error is missing the large or tension leak in a newborn already struggling to breathe; the acceptable one may be a borderline call on a tiny asymptomatic collection that a clinician would watch anyway. Accuracy statistics that do not separate these scenarios are, as the Inonu University authors make clear, answering a question nobody in the intensive care unit is asking. The next generation of validation studies, evaluated against intervention thresholds and severity strata, will determine whether deep learning can truly earn a place beside the neonatal radiologist, and whether its confidence can be trusted when a newborn’s collapsed lung is quietly becoming an emergency.

Subject of Research: Evaluation of deep learning models for detecting clinically significant neonatal pneumothorax on chest radiographs

Article Title: Beyond overall accuracy: Does an artificial intelligence model detect the neonatal pneumothoraces that matter most? Reply to Sanmoto et al.

Article References: Tatar, D., Yılmaz, E., & Köker Özer, N. (2026). Beyond overall accuracy: Does an artificial intelligence model detect the neonatal pneumothoraces that matter most? Reply to Sanmoto et al.. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06805-w

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06805-w

Keywords: artificial intelligence, deep learning, neonatal pneumothorax, pediatric radiology, chest radiography, computer-aided diagnosis, neonatology, model validation, tension pneumothorax, clinical significance, chest drain, matters arising

The finding matters because the assumption linking thyroid hormone restoration to weight reduction is deeply embedded in clinical practice and popular health culture. Hypothyroidism, the condition in which the thyroid gland produces insufficient hormone, is well known to slow metabolism, promote fluid retention and drive modest weight gain. Patients are frequently told that treatment will reverse these changes, and many report disappointment when the scale barely budges. By pooling data across multiple studies, the new analysis provides the kind of aggregated evidence that individual trials, often small and heterogeneous, cannot deliver on their own. The conclusion that emerges is nuanced: levothyroxine does what it is designed to do, restoring euthyroidism, but the downstream effects on body weight, body mass index and related measurements are too modest to justify expectations of substantial weight change.

To understand why the result is both unsurprising to specialists and surprising to patients, it helps to consider the physiology. Thyroid hormones regulate basal metabolic rate, thermogenesis, lipid metabolism and the balance between fat storage and fat oxidation. When hormone production falls, energy expenditure declines and the body tends to retain sodium and water, which contributes to weight gain that is partly a fluid phenomenon rather than an accumulation of fat. Levothyroxine, a synthetic form of thyroxine, or T4, replaces the missing hormone and, once doses are titrated to normalize thyroid-stimulating hormone levels, reverses these metabolic derangements. The metabolic machinery does restart. But the analysis suggests that the magnitude of weight change achieved once euthyroidism is restored is small, likely reflecting the resolution of fluid retention and only limited effects on fat mass in people whose hormone deficit has been corrected.

The distinction between statistical significance and clinical significance sits at the heart of the study’s message. Meta-analytic techniques can detect very small average effects by combining data from many participants, and pooled estimates often reach statistical significance even when the effect is trivially small in practical terms. The authors of the analysis explicitly frame their conclusion around this distinction. Weight and anthropometric parameters may shift measurably after levothyroxine-induced restoration of euthyroidism, but the shifts fall below thresholds that clinicians would consider meaningful for an individual patient. In weight management, a clinically significant change is generally one that contributes to health improvement, such as reductions of several percentage points in body weight or measurable improvements in waist circumference. Changes of a fraction of a kilogram, however consistent, do not meet that bar.

The implications for patient counseling are immediate. Endocrinologists and primary care physicians can now point to aggregated evidence when explaining that levothyroxine is not a weight-loss drug. This is not to dismiss the therapy’s value. Adequate thyroid hormone replacement is essential for cardiovascular health, cognitive function, energy levels, fertility and overall quality of life in people with hypothyroidism. The new analysis does not challenge any of those benefits. What it does challenge is the expectation, common among patients and occasionally among clinicians, that normalizing thyroid function will meaningfully reverse weight gain or serve as a gateway to weight reduction. Setting that expectation accurately may improve adherence and satisfaction, since patients who understand that the medication’s purpose is hormonal restoration rather than slimming are less likely to perceive treatment failure when the scale remains stable.

The findings also carry weight for the diagnostic gray zone that surrounds thyroid function and obesity. Subclinical hypothyroidism, in which thyroid-stimulating hormone is mildly elevated while free thyroxine remains normal, is widespread, and weight gain is often cited as a reason to treat. If restoring euthyroidism produces only clinically insignificant anthropometric changes, then weight concerns alone provide weak justification for initiating or escalating levothyroxine therapy, particularly in borderline cases. The analysis implicitly supports a more disciplined approach: treat thyroid dysfunction for its established indications, and manage weight through the evidence-based channels of diet, physical activity, behavioral intervention and, where appropriate, pharmacotherapy or metabolic surgery. Conflating the two risks unnecessary medication use and delayed attention to effective weight-management strategies.

Methodologically, the study reflects the current standards of evidence synthesis in endocrinology and obesity research. A systematic review protocol identifies all eligible studies of levothyroxine therapy aimed at restoring euthyroidism, extracts weight and anthropometric outcomes, and pools effect estimates with quantification of between-study heterogeneity. The meta-analytic framework allows the researchers to weigh each study by its precision, examine whether effects differ across populations and follow-up durations, and express results in ways that separate the size of an effect from the certainty that it exists. The title’s careful phrasing, that changes are clinically insignificant, signals that the pooled effects were assessed against explicit criteria for clinical relevance rather than statistical thresholds alone. That framing is increasingly demanded by journals and guideline bodies, which recognize that tiny average effects can be statistically robust yet meaningless at the bedside.

The publication also arrives at a moment of intense public interest in metabolism and body weight. GLP-1 receptor agonists have transformed expectations about what weight-loss treatment can achieve, producing double-digit percentage reductions in body weight in clinical trials. Against that backdrop, the modest anthropometric effects of levothyroxine stand out in sharp relief. The contrast may help recalibrate public understanding: thyroid hormone replacement corrects a deficiency, whereas dedicated weight-loss therapies act on appetite and metabolic pathways in ways designed to produce substantial energy deficits. Patients who hoped their thyroid prescription would work like an obesity medication now have quantitative evidence that it will not, and clinicians have a citable reference point for that conversation.

At the same time, the analysis leaves open questions that future research must address. Most importantly, the pooled results describe average effects, and averages can conceal subgroups. People with more severe or prolonged hypothyroidism, those with larger pretreatment weight gains, or individuals whose hypothyroidism resulted from thyroidectomy or ablative therapy might experience different trajectories than those with mild, recent-onset disease. The timing of assessment also matters, since weight changes related to fluid shifts may occur early, while any slower changes in fat mass would require longer follow-up to detect. Whether levothyroxine dose, baseline TSH level, age, sex or coexisting conditions modify the anthropometric response are exactly the kinds of questions that subgroup and sensitivity analyses in meta-research are designed to probe, and they remain fertile ground for further work.

For now, the practical takeaway is clear and, in its way, reassuring. Levothyroxine remains one of the most prescribed medications in the world because restoring euthyroidism genuinely restores health. The new systematic review and meta-analysis in the International Journal of Obesity adds an important piece of evidence-based clarity: patients and clinicians should expect the hormone levels to normalize, the symptoms of hypothyroidism to improve, and the metabolism to recover, but they should not expect the therapy to deliver meaningful weight loss. Weight management, the analysis implies, is a separate clinical project with its own tools. By quantifying just how little the scale moves when thyroid function returns to normal, the study closes a persistent gap between patient expectation and physiological reality, and it does so with the aggregated weight of evidence that only a systematic review can provide.

Subject of Research: The effect of levothyroxine-induced restoration of euthyroidism on body weight and anthropometric outcomes in a systematic review and meta-analysis

Article Title: Levothyroxine therapy for euthyroidism restoration results in clinically insignificant weight and anthropometric changes: a systematic review and meta-analysis

Article References: Wolde Sellasie, S., Ossola, N., Piticchio, T., Uccioli, L., & Trimboli, P. (2026). Levothyroxine therapy for euthyroidism restoration results in clinically insignificant weight and anthropometric changes: a systematic review and meta-analysis. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02224-x

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02224-x

Keywords: levothyroxine, hypothyroidism, euthyroidism, thyroid hormone, weight change, meta-analysis, systematic review, obesity, endocrinology, body mass index, thyroid-stimulating hormone, clinical significance